November 2024: minor clarifications concerning the discontinuation of liraglutide and semaglutide, supporting behavioural modifications when initiating incretin therapies, and contraindications
Why does glucagon agonism of retatrutide cause dysesthesia in 20,9% of subjects
Contribute now
Patients with type II diabetes and an elevated risk for atherosclerotic cardiovascular disease should be considered for GLP-1 agonist therapy regardless of hemoglobin A1c
Visit any of our Aspen Clinic locations across Louisiana, Baton Rouge, Covington, Hammond, Harvey, Houma, Lafayette, Metairie, Prairieville, and Slidell, or schedule an appointment today to get started!
High-purity research peptides: Every compound is independently tested by Janoshik before dispatch, with verifiable CoA documentation available for every batch